SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
HTG Molecular Diagnostics, Inc. (HTGMQ) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 31/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HTGMQ
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-24.28
Book Value / Share$0.00
Revenue / Share$7.16
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-6,354.98 |
$2.24M |
$-11.77M |
-524.7% |
| 2014 |
$-7,536.94 |
$3.33M |
$-13.96M |
-419.3% |
| 2015 |
$-905.40 |
$4.04M |
$-21.4M |
-529.4% |
| 2016 |
$-658.95 |
$5.13M |
$-26.04M |
-507.3% |
| 2017 |
$-322.04 |
$14.76M |
$-18.96M |
-128.5% |
| 2018 |
$-107.61 |
$21.5M |
$-16.45M |
-76.5% |
| 2019 |
$-91.17 |
$19.2M |
$-19.3M |
-100.5% |
| 2020 |
$-54.12 |
$8.55M |
$-20.87M |
-244.1% |
| 2021 |
$-29.66 |
$8.91M |
$-17.15M |
-192.5% |
| 2022 |
$-24.28 |
$6.37M |
$-21.59M |
-339.2% |
